Table 3.
Companies developing γδT-cell-based immunotherapies
| Company | Modality | T-cell type | Source | Autologous/allogeneic | Engineering | Comments |
|---|---|---|---|---|---|---|
| Adicet Bio | Cell therapy | Vδ1 | Blood | Allogeneic | CAR | - |
| Beijing Doing Biomedical | Cell therapy | Vδ2 | Blood | Autologous | Unmodified/CAR | - |
| Cytomed Therapeutics | Cell therapy | Vδ2 | Blood | Allogeneic | CAR | |
| Gadeta | Cell therapy | αβ | Blood | Autologous | Vδ2 TCR | - |
| GammaCell Biotechnologies | Cell therapy | Vδ2 | Blood | Autologous/allogeneic | Unmodified | - |
| GammaDelta Therapeutics | Cell therapy | Vδ1 | Skin/blood | Allogeneic | Unmodified/CAR | - |
| Hebei Senlang Biotechnology | Cell therapy | Vδ2 | Blood | Autologous | CAR/αβ TCR | - |
| Immatics | Cell therapy | Vδ2 | Blood | Allogeneic | αβ TCR | - |
| Incysus Therapeutics |
Cell therapy | Vδ2 | Blood | Autologous | Engineered | Engineered for chemotherapy resistance |
| PhosphoGam | Cell therapy | Vδ2 | Blood | Allogeneic | Unmodified | - |
| TC BioPharm | Cell therapy | Vδ1/Vδ2 | Blood | Autologous/allogeneic | Unmodified/CAR | - |
| Imcheck Therapeutics | Antibodies | Vδ2 | - | - | - | Activation of Vδ2 T cells (BTN3A) |
| Lava Therapeutics | T-cell engager | Vδ2 | - | - | - | Redirection of Vδ2 T cells against tumors |
| Nybo | Antibodies | Pan γδ | - | - | - | Depletion of inhibitory γδ T cells |
CAR, chimeric antigen receptor; TCR, T cell receptor.